Патогенетическое лечение рассеянного склероза препаратами, изменяющими его течение

1. Confraveux C, Aimard G, Devic M et al. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281–300.
2. Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag 2007; 3 (2): 259–68.
3. Buttmann M, Rieckmann P. Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother 2008; 8 (3): 433–55.
4. Macdonald JK, mcdonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007; 1: CD006097.
5. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 2004; 18 (6): 379–96.
6. Rudick RA, Stuart WH, Calabresi PA et al. SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354 (9): 911–23.
7. Polman CH, Uitdehaag BM. New and emerging treatment options for multiple sclerosis. Lancet Neurol 2003; 2 (9): 563–6.
8. Cree B. Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 2006; 12 (4): 171–8.
9. Natalizumab: new drug. Multiple sclerosis: risky market approval. Prescrire Int 2008; 17 (93): 7–10.
10. Elices MJ. Natalizumab. Elan/Biogen. Curr Opin Investig Drugs 2003; 4 (11): 1354–62.
11. Johnson KP. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis. Neurologist 2007; 13 (4): 182–7.
12. Langer-Gould A, Steinman L. Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab. Curr Neurol Neurosci Rep 2006; 6 (3): 253–8.
13. Kleinschmidt-demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353 (4): 369–74.
14. Http://www.fda.gov/Cder/drug/infopage/natalizumab/default.htm (28.05.2008)
15. Kappos L, Bates D, Hartung HP et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007; 6 (5): 431–41.
16. Langer-Gould A, Atlas SW, Green AJ et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353 (4): 375–81.
17. Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007; 29 (9): 2031–48.
18. Freedman MS, Hughes B, Mikol DD et al. Efficacy of Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis: A Systematic Comparison. Eur Neurol 2008; 60 (1): 1–11.
19. Barbero P, Bergui M, Versino E et al. INCOMIN Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. Mult Scler 2006; 12 (1): 72–6.
20. Goodin DS, Frohman EM, Hurwitz B et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68 (13): 977–84.
21. Francis GS, Rice GP, Alsop JC. PRISMS Study Group. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65 (1): 48–55.
22. Kappos L, Clanet M, Sandberg-Wollheim M et al. European Interferon Beta-1a IM Dose-Comparison Study Investigators. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65 (1): 40–7.
23. Freedman MS, Francis GS, Sanders EA et al. Once Weekly Interferon beta-1alpha for Multiple Sclerosis Study Group; University of British Columbia MS/MRI Research Group. Randomized study of once-weekly interferon beta-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 2005; 11 (1): 41–5.
24. Panitch H, Miller A, Paty D, Weinshenker B. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63 (10): 1788–95.
25. Rossman HS. Neutralizing antibodies to multiple sclerosis treatments. J Manag Care Pharm 2004; 10 (3 Suppl. B): S12–9.
26. Polman C, Barkhof F, Kappos L et al. European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler 2003; 9 (4): 342–8.
27. Ghezzi A. Immunomodulatory Treatment of Early Onset MS (ITEMS) Group. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Cooperative Study. Neurol Sci 2005; 26 (Suppl. 4): S183–6.
28. Pakdaman H, Sahraian MA, Fallah A et al. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurol Scand 2007; 115 (6): 429–31.
29. Lublin F. History of modern multiple sclerosis therapy. J Neurol 2005; 252 (Suppl. 3): iii3–iii9.
30. Kinkel RP, Kollman C, O'Connor P et al. CHAMPIONS Study Group. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66 (5): 678–84.
31. Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon b-1a dose response in relapsing-remitting MS. Neurology 1999; 53: 679–86.
32. Jacobs LD, Beck RW, Simon J et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898–904.
33. Barkhof F, Polman C, Radue E et al. Betaferon in newly emerging multiple sclerosis for initial treatment (BENEFIT): magnetic resonance imaging outcomes. ECTRIMS 2005; 2: 583.
34. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–7.
35. Cohen JA, Goodman AD, Heidenreich FR et al. Benefit of IFN beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679–86.
36. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498–504
37. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-b-1a in relapsing MS. Neurology 2001; 56: 1628–36.
38. Kappos L, Traboulsee A, Constantinescu C et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67: 944–53.
39. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 655.
40. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone) Eur J Neurol 2005; 12 (6): 425–31.
41. Khan OA, Tselis AC, Kamholz JA et al. A prospective, open-label treatment trial to compare the effect of IFN b-1a (Avonex), ifnb-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol 2001; 8 (2): 141–148.
42. Kappos L, Polman CH, Freedman MS et al. for the BENEFIT Study Group, Treatment with interferon beta-1b delays conversion to clinically definite and mcdonald MS in patients with clinically isolated syndromes Neurology 2006; 67: 1242–9.
43. Kappos L, Polman CH, Freedman MS et al. Treatment with interferon beta-1b delays conversion to clinically definite and mcdonald MS in patients with clinically isolated syndromes. Neurology 2007; 68: 1163.
44. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43 (4): 655–61.
45. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43 (4): 662–7.
46. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group Neurology. 1995; 45: 1277–85.
47. Http://www.fda.gov/bbs/topics/NEWS/NEW00424.html проверено 30.05.2008.
48. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39 (3): 285–94.
49. Khan OA, Tselis AC, Kamholz JA et al. A prospective, open-label treatment trial to compare the effect of ifnbeta-1a (Avonex), ifnbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing–remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 2001; 7 (6): 349–53.
50. Durelli L, Verdun E, Barbero P et al. Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359 (9316): 1453–60.
51. JOHNSON KP, BROOKS BR, COHEN JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. Neurology 1995; 45 (7): 1268–76.
52. JOHNSON KP, BROOKS BR, COHEN JA et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50 (3): 701–8.
53. Bornstein MB, Miller A, Slagle S et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991; 41 (4): 533–9.
54. Wolinsky JS, promise Study Group; Neurology 2001; 56 (Suppl. 3): A378–9.
55. Berger JR, Moskowitz L, Fischl M, Kelley RE. Neurological disease as the presenting manifestation of acquired immunodeficiency syndrome. South Med J 1987; 80: 683–6.
56. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002; 186 (suppl. 2): S180–S186.
57. Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD002127. DOI: 10.1002/14651858.CD002127.pub2.
58. Reggio E, Nicoletti A, Fiorilla T et al. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients– twenty-four months follow-up. J Neurol 2005; 252 (10): 1255–61.
59. Smith DR, Weinstock-Guttman B, Cohen JA et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 2005; 11 (5): 573–82.
60. Ytterberg C, Johansson S, Andersson M et al. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis. Acta Neurol Scand 2007; 116 (2): 96–9.
61. Polman CH, O'Connor PW, Havrdova E et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354 (9): 899–910.
62. Vollmer T, Panitch H, Bar-Or A et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008 Apr 18. Epub ahead of print.
63. Dhib-Jalbut S, Chen M, Henschel K et al. Effect of combined ifnbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler 2002; 8 (6): 485–91.
64. Deangelis T, Lublin F. Neurotherapeutics in multiple sclerosis: Novel agents and emerging treatment strategies. Mt Sinai J Med 2008; 75 (2): 157–67. Epub ahead of print.
65. Wingerchuk DM. Current evidence and therapeutic strategies for multiple sclerosis. Semin Neurol 2008; 28 (1): 56–68.
66. Http://www.biopartners.ch/mainnews387.htm
67. Li DK, O'Conner P, Freedman M et al. Oral teriflunomide is safe and effective in multiple sclerosis with relapses: results of a randomised, placebo-controlled Phase II study. Mult Scler 2004; 10 (Suppl. 2): P685.
68. O'Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66 (6): 894–900.
69. Minagar A, Alexander JS, Schwendimann RN et al. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol 2008; 65 (2): 199–204.
70. Kappos L, Radue EW, Antel J et al. FTY720 in relapsing MS: results of a double-blind placebo-controlled trial with a novel oral immunomodulator. Presented at The 15th European Neurological Society Meeting. Vienna (18–22 June 2005).
71. Polman C, Barkhof F, Sandberg-Wollheim M et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64 (6): 987–91.
72. Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363 (9421): 1607–8.
73. Giovannoni G, Barbarash O, Casset-Semanaz F et al. RNF Study Group. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase iiib study in adults with multiple sclerosis. Clin Ther 2007; 29 (6): 1128–45.
74. Chofflon M. Mechanisms of action for treatments in multiple sclerosis. Does a heterogeneous disease demand a multi-targeted therapeutic approach? Biodrugs 2005; 19 (5): 299–308.
75. Bielekova B, Richert N, Howard T et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004; 101 (23): 8705–8.
76. BioMS Medical Press Release December 17, 2007.
77. Casetta I, Iuliano G, Filippini G. Cochrane Database of Systematic Rev 2007; 4.
78. Teva Pharmaceutical Industries Ltd. (07/11/07).
79. American Academy of Neurology (16/04/08).
80. Wakkee M, Thio HB. Drug evaluation: BG-12, an immunomodulatory dimethylfumarate. Curr Opin Investig Drugs 2007; 8 (11): 955–62.
81. Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin 2007; 23 (11): 2667–76.
82. 23d Congress of the European Committee for the Treatment and Research in Multiple Sclerosis: Parallel session 9 (119). Presented October 14, 2007.
83. Hartung HP. Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol 2005; 252 (Suppl. 3): iii44–iii50.
84. Sabat_ E. (ed.) Adherence to Long term Therapies: Evidence for Action. World Health Organization. Geneva 2003.
85. Patient Compliance with statins. Bandolier Review, 2004.
86. Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med 2005; 353: 487–97.
87. Not to be taken as directed – Putting concordance for taking medicines into practice. BMJ 2003; 326: 348–9.
88. Pharm J 2005; 275 (Suppl.).
89. http://en.wikipedia.org/wiki/Compliance_medicine
90. Бойко А.Н., Давыдовская М.В., Демина Т.Л. и др. Опыт длительного использования Бетаферона и Копаксона в повседневной практике неврологов – результаты 5-летнего лечения больных рассеянным склерозом в Московском городском центре рассеянного склероза. Журн. неврол. психиат. (Спец. выпуск 4. «Рассеянный склероз»). 2007; 84–94.
91. The interferon Beta-1b 16-year long-term follow-up study: The final results. Abstract P01.079AAN, San Diego, 5 Apr 2006.